Market-Pulse.com - Current Profile - (Arrayit Corporation [OTCBB:
ARYC])
Welcome to Market Pulse`s
online newsletter. Market Pulse is a
small-cap investor`s first stop Web page. Each month, our user-friendly Web site profiles new
and emerging companies that have excellent potential. We also feature quotes, charts, SEC
filings, news headlines, previous profiles of featured companies and other valuable information
that is easily accessed. We recommend that anyone investing perform his or her own due
diligence.
Market Pulse has
issued its current profile for Arrayit Corporation (OTCBB: ARYC) to the investment community!
Stay Tuned For Frequent
Updates at www.market-pulse.com .
Arrayit Corporation
(OTCBB: ARYC)
is engaged in the development, manufacture, and marketing of life science
technologies and integrated systems for the analysis of genetic variation, biological function,
and diagnostics. Arrayit offers a product line of approximately 650 tools to 2,500
laboratories worldwide. The company’s products include microarrayers, microarray scanners,
DNA and protein microarrays, microarray printing, microarray substrates and slides, microarray
instruments, amplification and labeling, purification kits, microarray hardware, buffers and
solutions, microarray cleanrooms, books and software, CGH microarrays, and microarray platforms.
Arrayit’s worldwide business position leverages the company’s widely used patented
microarray manufacturing platform and revolutionary VIP™ genotyping technology. Nearly
every major research center in the world uses Arrayit products including research laboratories,
pharmaceutical companies, universities, biotechnology companies, hospitals, government agencies,
and nonprofit research organizations. The company is also involved in the import, export, and
distribution of industrial and food grade chemicals for plastics, fertilizers, and green energy
applications. It has research collaboration with The Parkinson`s Institute of Sunnyvale to
discover biomarkers for Parkinson`s disease. ARYC recently announced that it is developing a
microarray-based diagnostic test to detect the H1N1 swine flu virus. The 2009 swine flu outbreak
has raised concerns at the CDC and the World Health Organization (WHO). The CDC and WHO believe
that the current outbreak poses a pandemic risk because the H1N1 flu virus contains genetic
elements from both the swine and human influenza viruses, allowing direct human-to-human
transmission without the need for agricultural contact. Arrayit is an exciting and innovative
public company that strives to increase shareholder equity by inventing, developing,
manufacturing and supplying sophisticated life sciences products and services to an extensive
customer base spanning 50 countries. Arrayit is a leader in the field of molecular diagnostics
with patented technology that allows the screening and monitoring of up to 80,000 patient samples
on a single microscope slide, rather than testing one patient per slide as is currently
practiced. Their corporate philosophy is embodied by a highly skilled, multidisciplinary team
of investors, business professionals, scientists, engineers and executive and support staff who
place shareholder value, product quality, customer service and price competitiveness as their
highest priorities. Arrayit empowers decisive strategic advantage and large return on investment
for their customers in the research, pharmaceutical, diagnostic, and health care
markets!
Press
Release
Source: Arrayit
Corporation
Major News Media Missed
the Mark -- There Is a New Pre-Symptomatic Screening Test for Ovarian Cancer Coming From Arrayit
Corporation, and It Will Be Available Soon
Noninvasive Test Will Provide
Hope for 90% of Women Diagnosed With This Silent Killer
SUNNYVALE, CA--(Marketwire -
01/07/10) - On December 9th, 2009, Arrayit Corporation (OTCBB: ARYC) , a leading
manufacturer of products and services for disease prevention, treatment and cure, announced a
breakthrough in ovarian cancer screening utilizing a microarray-based diagnostic test that will
detect whether a patient is pre-symptomatic for this silent killer.
In a report
by NBC`s Dr. Robert Bezell on Tuesday, January 5th, it was reported that although research
continues, there is no effective screening test currently available to detect the pre-symptomatic
presence of ovarian cancer. The report missed the mark, which indicates that press information
distributed by Arrayit on December 9th, somehow fell through the cracks. The fact is, Arrayit`s
advanced screening test, OvaDx(TM), will be available very soon.
Researchers at a major cancer
research institute have worked for six years to identify more than 100 biomarkers unique to
ovarian cancer. The proteomic markers were finally identified using a novel and patented
microarray platform created by Arrayit. A noninvasive screening test can be performed via a
simple blood test that can be conducted during annual physical exams. The test will soon be
submitted to the FDA for approval, and since it is an in vitro diagnostic multivariate index
assay, prompt approval is anticipated.
According to the American Cancer
Society, more than 21,500 women will be diagnosed with Ovarian Cancer this year, and 14,000 will
die. Up until now, screening tests could only detect the `Silent Killer` when the disease is
symptomatic, meaning the disease has progressed to stage 3 or 4. Unfortunately at this late stage
of detection the cancer most certainly has metastasized and spread beyond the ovary, which proves
fatal for 75% of women diagnosed.
Ovarian cancer ranks fifth in
cancer deaths among women, accounting for more deaths than any other cancer of the female
reproductive system. Clinicians state that the primary reasons for such a high fatality rate are
that there are no discernable early symptoms, and there has not been an effective early detection
test available. The American Cancer Society estimates that 90% of woman diagnosed with ovarian
cancer could survive with early detection. Currently only 20% of women diagnosed are in the
early stages.
The early detection of ovarian
cancer holds tremendous potential to profoundly impact the quality of life of ovarian cancer
victims and shift costs from treatment to detection ensuring survivability for a larger
population. Upon FDA approval, OvaDx(TM) will be marketed and sold by Arrayit Corporation`s
subsidiary, Arrayit Diagnostics (Ovarian), Inc., in Houston, Texas under a licensing
agreement.
About
Arrayit
Arrayit Corporation (OTCBB: ARYC),
headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical,
and diagnostic communities through the discovery, development and manufacture of proprietary life
science technologies and consumables for disease prevention, treatment and cure. Arrayit now
offers over 650 products to a customer base of more than 10,000 clinics and research facilities,
and more than 5,000 laboratories worldwide, including most every major university,
pharmaceutical and biotech company, major agricultural and chemical company, government agency,
national research foundation and many private sector enterprises. Please visit www.arrayit.com
for more information.
Contact: Investor Contact: Arrayit Corporation Tel: 281-600-5000
investorinfo@arrayit.com www.arrayit.com
Media Contact: Rod Mitchell Tel:
281-350-5506 Email: mediarod@aol.com
For additional information please
call 800.290.8935 or visit www.market-pulse.com .
Safe Harbor Statement
Except for historical information contained herein, statements
made in this release that constitute forward-looking statements are based on currently available
information, involve certain risks and uncertainties and the Company assumes no responsibility
to update any such forward-looking statement. The following factors, among others, may cause
actual results to differ materially from the results suggested in the forward-looking statements.
Risks that may result from changes in the Company`s business operations; our ability to keep pace
with technological advances; significant competition in the biomedical business; our
relationships with key suppliers and customers; quality and consumer acceptance of newly
introduced products; market volatility; non-availability of product; excess inventory; price and
product competition; new product introductions, the outcome of our legal disputes; the
possibility that the review of our prior filings by the SEC may result in changes to our
financial statements; and the possibility that stockholders or regulatory authorities may
initiate proceedings against Arrayit and/or our officers and directors as a result of any
restatements. Risk factors associated with our business, including some of the facts set forth
herein, are detailed in the Company`s Form 10-K/A for the fiscal year ended December 31, 2008 and
Form 10-Q/A for the fiscal first quarter ended March 31, 2009, Form 10-Q/A for the fiscal second
quarter ended June 30, 2009 and Form 10-Q for the fiscal third quarter ended September 30,
2009.
Market Pulse All Rights Reserved.
© Copyright 2010
------------------------------------------------------------
Disclaimer/Disclosure
The publisher of this email is
Market Pulse, which is an independent electronic online newsletter that is owned by Market Pulse LLC
(MP).
Market Pulse (MP) is an investor
or public relations firm which concentrates on promoting awareness among brokers, investors, and
others in the investment community of small and micro-cap companies which otherwise have difficulty
receiving coverage in the financial press. MP typically performs that service by profiling the
companies on its Web sites, or by direct mailings to its database of members of the investment
community.
Companies featured on Market
Pulse`s online newsletter pay consideration, which may include cash and/or shares of stock, to MP
for dissemination of company information and, in some cases, for consulting services. When MP
receives shares as compensation for investor relations, public relations, or consulting services for
a featured company, MP may sell part or all of any such shares during the period in which MP is
performing such services. MP`s services for a company may cause the company`s stock price to
increase, in which event MP would make a profit when it sells its stock in the company. In addition,
MP`s selling of a company`s stock may have a negative effect on the market price of the stock. All
statements and expressions are the opinion of the companies featured and are not meant to be a
solicitation or recommendation to buy, sell, or hold securities. MP is not a registered investment
advisor or a broker dealer. While it is MP`s goal to feature equity investments in micro or small
capitalization companies that have the potential for long-term appreciation, investments in the
companies reviewed are considered to be a high risk and use of the information provided is at the
investor`s sole risk. MP shall not be liable for any loss, damage, or expense of any kind resulting
from the purchase of securities of a profiled company. MP may act as a consultant to the companies
reviewed in this publication and may be remunerated by these companies or its shareholders for
investor relation services.
Information contained herein is
the opinion of MP and is intended to be used strictly for informational purposes. You should be
aware that MP attempts to assure itself of the accuracy of the information contained in the analyses
it publishes. In this regard, MP does, at times, rely on the accuracy of information supplied to it
by the companies which are the subject of MP`s analyses and/or parties related to those companies.
MP also relies on the accuracy and integrity of information that is contained in company press
releases and reports filed with the SEC. The companies mentioned in this publication have not
approved the content or timing of the information being published unless otherwise noted. MP,
because it relies on information supplied by various third parties disclaims any responsibility for
the accuracy of such information. Any investor considering making an investment in any security
which has been the subject of a MP analysis or opinion should, before making any such investment,
consult with his/her market professional and/or do his/her own independent research regarding the
company which is the subject of an MP opinion, recommendation or analysis. Information regarding
companies which MP has opined upon is normally available from many sources including the subject
company’s filings with the SEC and various press releases issued by the
company.
The information that MP relies on is generally provided by
the featured companies and also may include information from outside sources and interviews
conducted by MP. While MP believes all sources of the information to be reliable, MP makes no
representation or warranty as to the accuracy of the information provided. Investors should not rely
solely on the information contained in this publication. Rather, investors should use the
information contained in this publication as a starting point for doing additional independent
research on the featured companies. Factual statements in this publication are made as of the date
stated and are subject to change without notice. Nothing in this publication shall constitute a
representation or warranty that there has been no change in the affairs of the company since the
date of MP`s profile of the company. MP and/or its officers, directors, or affiliates have received
compensation for the dissemination of information on the companies which are the subject of profiles
and/or may have, from time to time, a position in the securities with the intent to sell the
securities mentioned herein. The profiles in the publication are believed to be reliable; however
the publisher disclaims any and all liability as to the completeness or accuracy of the information
contained in any profile and for any omissions of material facts from such profile. The profiles
within this publication are not to be construed as offers to purchase securities in the companies
which may be the subject of such profiles pursuant to federal or state law or the laws of any
foreign jurisdiction. MP or MP`s affiliates, agents, and/or relatives thereof may have interests or
positions in equity securities of the companies reviewed in this email, some or all of which may
have been acquired prior to the dissemination of this report, and may increase or decrease these
positions at any time. MP has been compensated, in connection with its profile of Arrayit
Corporation, one hundred thousand shares of Arrayit Corporation`s common stock by a third party
shareholder. Additionally, MP bought for its own account in the open market, forty thousand shares
of Arrayit Corporation`s shares for a total purchase price of twenty three thousand eight hundred
twenty dollars. To date, MP has sold seventy thousand shares of stock in Arrayit Corporation for
proceeds totaling sixty five thousand seven hundred twenty three dollars.
MP may be retained as a
consultant for one to twelve months to companies that we feature. Investing in micro-cap and growth
securities is highly speculative and carries an extremely high degree of risk. It is possible that
an investor`s investment may be lost or impaired due to the speculative nature of the companies
profiled. We encourage our readers to invest carefully and read the investor information available
at the web sites of the Securities and Exchange Commission ("SEC") at www.sec.gov
and/or The Financial Industry Regulatory Authority ("FINRA") at www.finra.org .
Postal Address: Market Pulse, 4279
Roswell Road, Suite 102 #239, Atlanta, GA 30342.
To
See Market Pulse's website for full disclaimer. Market Pulse may have received compensation for stock picks.
Home
